TMEM44 as a Novel Prognostic Marker for Kidney Renal Clear Cell Carcinoma is Associated with Tumor Invasion, Migration and Immune Infiltration.

Immune Infiltration Kidney clear cell carcinoma Prognostic factor TMEM44 Transmembrane proteins family

Journal

Biochemical genetics
ISSN: 1573-4927
Titre abrégé: Biochem Genet
Pays: United States
ID NLM: 0126611

Informations de publication

Date de publication:
10 Aug 2023
Historique:
received: 27 04 2023
accepted: 18 07 2023
medline: 10 8 2023
pubmed: 10 8 2023
entrez: 10 8 2023
Statut: aheadofprint

Résumé

Transmembrane (TMEM) proteins are integral membrane proteins that traverse biological membranes. Several members of the TMEM family have been linked to the development and progression of various tumors. However, the specific role and mechanism of TMEM44 in tumor biology remain largely unexplored. In this study, we initially conducted an extensive analysis using the TCGA database to investigate the expression patterns and survival associations of TMEM44 across various human tumors. Subsequently, we focused on KIRC and found a significant correlation between TMEM44 expression and this particular cancer type. To validate our findings, we performed western blot and quantitative polymerase chain reaction (qPCR) assays to confirm the expression levels of TMEM44 in KIRC. Following this, we employed a series of functional assays, including CCK8 viability assay, EDU incorporation assay, wound healing assay, and transwell migration assay, to investigate the biological role of TMEM44 in KIRC. We observed a significant upregulation of TMEM44 expression in KIRC, indicating its potential involvement in the pathogenesis of this cancer. We intervened in the expression of TMEM44 in KIRC cells and found significant inhibitory effects on cell proliferation, migration, and invasion in KIRC cells. Furthermore, our findings indicated that TMEM44 could serve as an independent prognostic factor in KIRC, highlighting its potential clinical significance. Consequently, TMEM44 holds promise as both a prognostic biomarker and a prospective therapeutic target for KIRC.

Identifiants

pubmed: 37561335
doi: 10.1007/s10528-023-10466-x
pii: 10.1007/s10528-023-10466-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Natural Science Foundation of China
ID : 82060463
Organisme : Key Research and Development Program of Jiangxi Province
ID : 20202BBGL73088

Informations de copyright

© 2023. The Author(s).

Références

Bian E et al (2021) Super-enhancer-associated TMEM44-AS1 aggravated glioma progression by forming a positive feedback loop with myc. J Experimental Clin Cancer Research: CR 40(1):337
doi: 10.1186/s13046-021-02129-9 pmcid: 8543865
de Leon M et al (2016) Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer. Gynecol Oncol 142(3):539–547
doi: 10.1016/j.ygyno.2016.06.017 pubmed: 27374141 pmcid: 4993677
Duan J et al (2021) TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma. Aging 13(4):5585–5606
doi: 10.18632/aging.202487 pubmed: 33591950 pmcid: 7950261
Flamant L et al (2012) TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer 12:391
doi: 10.1186/1471-2407-12-391 pubmed: 22954140 pmcid: 3519606
Foulquier F et al (2012) TMEM165 deficiency causes a congenital disorder of glycosylation. Am J Hum Genet 91(1):15–26
doi: 10.1016/j.ajhg.2012.05.002 pubmed: 22683087 pmcid: 3397274
Guo J et al (2015) Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells. Oncol Rep 33(6):3124–3130
doi: 10.3892/or.2015.3902 pubmed: 25872785
Hrašovec S et al (2013) TMEM25 is a candidate biomarker methylated and down-regulated in colorectal cancer. Dis Markers, 34(2)
Jiang H et al (2021) Upregulation of TMEM45A promoted the progression of Clear Cell Renal Cell Carcinoma in vitro. J Inflamm Res 14:6421–6430
doi: 10.2147/JIR.S341596 pubmed: 34880644 pmcid: 8646231
Ma W et al (2022) High VSX1 expression promotes the aggressiveness of clear cell renal cell carcinoma by transcriptionally regulating FKBP10. J Translational Med 20(1):554
doi: 10.1186/s12967-022-03772-2
Rao J et al (2020) TMEM205 is an independent prognostic factor and is Associated with Immune Cell infiltrates in Hepatocellular Carcinoma. Front Genet 11:575776
doi: 10.3389/fgene.2020.575776 pubmed: 33193690 pmcid: 7592400
Schmit K, Michiels C (2018) TMEM Proteins in Cancer: a review. Front Pharmacol 9:1345
doi: 10.3389/fphar.2018.01345 pubmed: 30574087 pmcid: 6291505
Shen K et al (2018) Knockdown of TMEM45B inhibits cell proliferation and invasion in gastric cancer, vol 104. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, pp 576–581
Thomas-Gatewood C et al (2011) TMEM16A channels generate Ca
doi: 10.1152/ajpheart.00404.2011 pubmed: 21856902 pmcid: 3213970
Vinothkumar KR, Henderson R (2010) Structures of membrane proteins. Q Rev Biophys, 43(1)
von Heijne G (2006) Membrane-protein topology. Nat Rev Mol Cell Biol 7(12):909–918
doi: 10.1038/nrm2063
Zhao H et al (2017) TMEM88 inhibits extracellular matrix expression in keloid fibroblasts, vol 95. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, pp 1436–1440
Zhou M et al (2022) Chitosan-Gelatin-EGCG nanoparticle-meditated LncRNA TMEM44-AS1 silencing to activate the P53 signaling pathway for the synergistic reversal of 5-FU resistance in gastric Cancer. Adv Sci (Weinheim Baden-Wurttemberg Germany) 9(22):e2105077

Auteurs

Jie Tian (J)

Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Liang Sun (L)

Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Lisong Wan (L)

Department of Organ Transplantation, Jiangxi Provincial People's Hospital, Nanchang, China.

Haibin Zou (H)

Trauma Center, Shangrao People's Hospital, Shangrao, China.

Jitao Chen (J)

Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Fei Liu (F)

Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. phiger81@163.com.

Classifications MeSH